IL10 and neoplasm: Moreover, i.v. vaccination with the liposome-containing tumour antigens and IL-10 siRNA induced type- I- interferon production and cytotoxic T cell responses against tumour cells, further supporting the use of lipid based nano-carrier agents for the activation of DCs in situ as well.